Your liver cells have tiny power plants called mitochondria that generate energy and control how your body processes fat. **When these mitochondria malfunction, fat accumulates in your liver, triggering a cascade of damage that can lead to cirrhosis and liver failure.** A comprehensive new review published in Frontiers in Molecular Biosciences reveals exactly how this happens, and the findings are reshaping how researchers approach treatment for non-alcoholic fatty liver disease (NAFLD), a condition affecting roughly one in five adults globally. What Are Mitochondrial Complexes and Why Do They Matter for Liver Health? Mitochondria contain five specialized protein complexes, labeled I through V, that work together like an assembly line to convert nutrients into usable energy (ATP) and manage fat metabolism. When these complexes become damaged or dysfunctional, two dangerous things happen simultaneously: your liver cells lose the energy they need to burn fat, and they produce excessive reactive oxygen species (ROS), which are unstable molecules that damage cells and trigger inflammation. This double hit accelerates the progression from simple fatty liver to more severe conditions like non-alcoholic steatohepatitis (NASH), fibrosis, and eventually cirrhosis. The research shows that NAFLD is fundamentally a mitochondrial disease. Across dozens of studies examining different animal models and human patients, scientists consistently found that mitochondrial complexes I, II, III, IV, and V all show reduced activity and impaired function in people with fatty liver disease. Complex I dysfunction appears most frequently in the research, but all five complexes contribute to the disease process. How Do Damaged Mitochondria Cause Fat to Build Up in the Liver? When mitochondrial complexes malfunction, your liver cells cannot efficiently oxidize (burn) fatty acids for energy. Instead of being converted into usable fuel, these fats accumulate as lipid droplets inside hepatocytes, the liver's main functional cells. Simultaneously, the damaged mitochondria pump out excessive reactive oxygen species, which triggers inflammatory responses and oxidative stress. This combination of impaired fat burning and cellular damage creates a vicious cycle: more fat accumulates, more oxidative stress develops, and the liver becomes increasingly inflamed and fibrotic. The review identified specific protein subunits within mitochondrial complexes that appear particularly vulnerable in NAFLD. For example, studies found reduced expression of NDUFS2 and NDUFA10 (subunits of complex I) in people with obesity and liver steatosis, while other research documented decreased levels of NDUFB8 and NDUFB9 in obese patients with liver steatosis. These specific molecular changes offer researchers precise targets for new therapies. Why Is the Pharmaceutical Industry Racing to Target Mitochondrial Dysfunction? The recognition that mitochondrial dysfunction drives NAFLD has triggered an unprecedented surge in drug development. According to a 2026 market analysis, more than 90 pharmaceutical and biotechnology companies are now advancing over 100 drug candidates targeting NAFLD and NASH. This represents one of the most active therapeutic pipelines in liver disease research, driven by the fact that currently no FDA-approved medications specifically treat NAFLD despite its massive global burden. The pipeline includes drugs at every stage of development, from early-stage compounds to late-stage Phase III trials. These therapies employ diverse mechanisms of action, targeting metabolic dysfunction, inflammation, fibrosis, and lipid metabolism. Some of the most advanced candidates include resmetirom (Madrigal Pharmaceuticals), which completed enrollment of 845 patients in its pivotal Phase III MAESTRO-NASH OUTCOMES trial in October 2024, and belapectin (Galectin Therapeutics), which released Phase III data in December 2024 for patients with MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis and portal hypertension. What Types of Treatments Are Being Developed? The emerging NAFLD drug pipeline reflects remarkable diversity in therapeutic approaches. Companies are developing treatments across multiple drug classes and delivery methods: - Small Molecules: Oral medications like resmetirom and lanifibranor that can be taken as pills, offering convenience for patients managing chronic liver disease. - Peptides and Biologics: Injectable therapies like efruxifermin (Akero Therapeutics) and efinopegdutide (Merck) that work through subcutaneous or intravenous administration to target specific metabolic pathways. - Oligonucleotides: Advanced genetic therapies that modify how liver cells express disease-driving proteins, representing cutting-edge molecular medicine approaches. Key companies driving innovation include Eli Lilly, AstraZeneca, Inventiva Pharma, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and Merck, among many others. The diversity of mechanisms reflects the complexity of NAFLD: no single target will likely work for all patients, so the industry is pursuing multiple pathways simultaneously. How to Monitor Your Liver Health While New Treatments Develop If you have risk factors for NAFLD, such as obesity, type 2 diabetes, or metabolic syndrome, several strategies can help you stay informed about your liver status: - Regular Blood Work: Ask your doctor to monitor liver enzymes (ALT and AST) and other markers of liver function annually, especially if you have metabolic risk factors. - Non-Invasive Imaging: Discuss with your healthcare provider whether non-invasive tests like FibroScan ultrasound or advanced MRI imaging are appropriate for assessing liver fat and fibrosis without requiring a biopsy. - Clinical Trial Participation: If you have confirmed NAFLD or NASH, ask whether you might be eligible for clinical trials testing new therapies, which often provide access to cutting-edge treatments and close medical monitoring. Major academic medical centers, including UC San Diego, are actively enrolling patients in NAFLD clinical trials. The SYNERGY-OUTCOMES study, for example, is enrolling approximately 4,500 adults to test whether newer medications like retatrutide and tirzepatide can prevent major adverse liver outcomes in people with metabolic dysfunction-associated steatotic liver disease (MASLD), the updated term for NAFLD. Participants in such trials typically have 25 to 30 clinic visits over the study period, with comprehensive monitoring of liver function and disease progression. What Does This Mean for Patients Right Now? While mitochondrial-targeting therapies are still in development, the scientific understanding of how mitochondrial dysfunction drives NAFLD offers hope. The fact that over 100 drug candidates are in active development suggests that effective treatments could reach patients within the next few years. In the meantime, lifestyle modifications remain the most evidence-based approach: weight loss, reduced sugar and refined carbohydrate intake, increased physical activity, and management of metabolic conditions like diabetes and high cholesterol all help preserve mitochondrial function and slow NAFLD progression. The convergence of basic science discoveries about mitochondrial complexes and aggressive pharmaceutical development represents a turning point in liver disease treatment. For the first time, researchers understand the precise cellular mechanisms driving NAFLD, and the industry is responding with unprecedented investment. Patients with fatty liver disease should discuss their individual risk factors and potential eligibility for clinical trials with their healthcare providers, as the next generation of NAFLD treatments may offer transformative benefits.
